Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

NCT04969276 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

306

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza Immunization
Healthy Volunteers

Interventions

BIOLOGICAL: Quadrivalent Inactivated Influenza High Dose
BIOLOGICAL: COVID-19 mRNA Vaccine (nucleoside modified)

Sponsor

Sanofi Pasteur, a Sanofi Company